Efficacy and utility of antifibrinolytics in pediatric spine surgery: a systematic review and network meta-analysis.
Sepehr AghajanianFateme MohammadifardOmid Kohandel GargariArvin NaeimiAyad BahadorimonfaredAladine A ElsamadicyPublished in: Neurosurgical review (2024)
Antifibrinolytics have gained increasing attention in minimizing blood loss and mitigating the risks associated with massive transfusions, including infection and coagulopathy in pediatric patients undergoing spine surgery. Nevertheless, the selection of optimal agent is still a matter of debate. We aim to review the utility of these agents and compare the efficacy of antifibrinolytics in pediatric and adolescent spine surgeries. A comprehensive search was performed in Scopus, Web of Science, and MEDLINE databases for relevant works. Studies providing quantitative data on predefined outcomes were included. Primary outcome was perioperative bleeding between the groups. Secondary outcomes included transfusion volume, rate of complications, and operation time. Twenty-eight studies were included in the meta-analysis incorporating 2553 patients. The use of Tranexamic acid (RoM: 0.71, 95%CI: [0.62-0.81], p < 0.001, I 2 = 88%), Aprotinin (RoM: 0.54, 95%CI: [0.46-0.64], p < 0.001, I 2 = 0%), and Epsilon-aminocaproic acid (RoM: 0.71, 95%CI: [0.62-0.81], p < 0.001, I 2 = 60%) led to a 29%, 46%, and 29% reduction in perioperative blood loss, respectively. Network meta-analysis revealed higher probability of efficacy with Tranexamic acid compared to Epsilon-aminocaproic acid (P score: 0.924 vs. 0.571). The rate of complications was not statistically different between each two antifibrinolytic agent or antifibrinolytics compared to placebo or standard of care. Our network meta-analysis suggests a superior efficacy of all antifibrinolytics compared to standard of care/placebo in reducing blood loss and transfusion rate. Further adequately-powered randomized clinical trials are recommended to reach definite conclusion on comparative performance of these agents and to also provide robust objective assessments and standardized outcome data and safety profile on antifibrinolytics in pediatric and adolescent pediatric surgeries.
Keyphrases
- systematic review
- patients undergoing
- case control
- cardiac surgery
- meta analyses
- healthcare
- end stage renal disease
- young adults
- palliative care
- ejection fraction
- risk factors
- public health
- newly diagnosed
- big data
- quality improvement
- peritoneal dialysis
- chronic kidney disease
- prognostic factors
- electronic health record
- high resolution
- metabolic syndrome
- single cell
- mass spectrometry
- type diabetes
- insulin resistance
- clinical trial
- artificial intelligence
- phase iii
- affordable care act
- open label
- pain management
- patient reported outcomes
- double blind